Antibody–drug conjugates (ADCs)—new targeted therapies

ISSN： 1865-5041

Source： memo - Magazine of European Medical Oncology, Vol.6, Iss.4, 2013-12, pp. : 223-224

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Advances in Anticancer Antibody-Drug Conjugates and Immunotoxins

Recent Patents on Anti-Cancer Drug Discovery, Vol. 9, Iss. 1, 2014-01 ,pp. : 35-65

Bentham Science Publishers

Access to resources Recommend Favorite

Antibody–drug conjugates for the treatment of B-cell non-Hodgkin’s lymphoma and leukemia

By Chu Yu-Waye Polson Andrew

Future Oncology, Vol. 9, Iss. 3, 2013-03 ,pp. : 355-368

Future Medicine

Access to resources Recommend Favorite

2. New Targeted Therapies for CLL

International Journal of Cancer Research and Prevention, Vol. , Iss. , 2017-01 ,pp. : 69-81

Nova Science Publishers, Inc.

Access to resources Recommend Favorite

Heterocyclic Drug-polymer Conjugates for Cancer Targeted Drug Delivery

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 16, Iss. 11, 2016-10 ,pp. : 1355-1377

Bentham Science Publishers

Access to resources Recommend Favorite

Advances in the Development of Site-Specific Antibody-Drug Conjugation

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 15, Iss. 7, 2015-01 ,pp. : 828-836

Bentham Science Publishers

Access to resources Recommend Favorite